• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 7:06:51 AM ET
    $CDAK
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CDAK alert in real time by email
    SC 13G 1 sc13g.htm
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
    ______________

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934




    Codiak Biosciences, Inc.
    (Name of Issuer)

    Common Stock, $0.0001 par value
    (Title of Class of Securities)

    192010106
    (CUSIP Number)

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:


    [   ]
    Rule 13d-1(b)


    [X]
    Rule 13d-1(c)


    [   ]
    Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

    (Continued on following pages)

    CUSIP No. 192010106
    1
    NAME OF REPORTING PERSONS
     
    Alaska Permanent Fund Corporation
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)  ☐
    (b)  ☐
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Alaska
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
    0
     
    6
    SHARED VOTING POWER
    0
     
    7
    SOLE DISPOSITIVE POWER
    0
     
    8
    SHARED DISPOSITIVE POWER
    4,422,895
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    4,422,895
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    23.56%*
     
    12
    TYPE OF REPORTING PERSON
    OO
     
    *
    Percentage calculated based on 18,767,674 shares of common stock, par value $0.0001 per share, being the shares of common stock outstanding as of November 19, 2020 as reported on the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 19, 2020.

    Item 1(a). Name of Issuer:
     
     
     
    Codiak Biosciences, Inc.
     
     
    Item 1(b).
    Address of Issuer’s Principal Executive Offices:
     
     
     
    499 Illinois Street, Suite 500, San Francisco, California 94158.
     
     
    Item 2(a). Name of Person Filing:
     
     
     
    This Schedule 13G is being filed by the Alaska Permanent Fund Corporation with respect to the Common Stock, par value $0.0001 per share or Codiak Biosciences, Inc.
     
     
    Item 2(b). Address of Principal Business Office or, if None, Residence:
     
     
     
    The address of the principal business office of the Reporting Person is 801 West 10th Street, Suite 302, Juneau, Alaska, 99801.
     
     
    Item 2(c). Citizenship:
     
     
     
    The Reporting Person is the Alaska Permanent Fund Corporation, acting for and on behalf of the funds which the Alaska Permanent Fund Corporation is designated by Alaska Statutes 37.13 to manage and invest.
     
     
    Item 2(d). Title of Class of Securities:
       
      Common Stock, par value $0.0001 per share.
       
    Item 2(e). CUSIP Number:
       
      192010106
       
    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
       

    Not applicable.
       
    Item 4. Ownership.
       
      (a)
    Amount beneficially owned as of December 31, 2020:
         
        (i)
    Yukon Investors, LLC directly owns 568,797 shares of the Issuer’s common stock. The Reporting Person is a member of Yukon Investors, LLC, and may be deemed to beneficially own the shares held by it.
           
        (ii)
    ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P. directly own 3,854,098 shares of the Issuer’s common stock. The Reporting Person is a limited partner in each of ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P. and may be deemed to beneficially own the shares held by such funds.

      (b)
    Percent of class:
         
        See Row 11 of the cover page for the Reporting Person.
         
      (c)
    Number of shares as to which the Reporting Person has:
         
        (i)
    Sole power to vote or to direct the vote
           
         
    See Row 5 of the cover page for the Reporting Person.
           
        (ii)
    Shares power to vote or to direct the vote:
           
          See Row 6 of the cover page for the Reporting Person.
           
        (iii)
    Sole power to dispose or to direct the disposition of:
           
          See Row 7 of the cover page for the Reporting Person.
           
        (iv)
    Shared power to dispose or to direct the disposition of:
           
          See Row 8 of the cover page for the Reporting Person.
         
    Item 5.
    Ownership of Five Percent or Less of a Class.
       
     
    Not applicable.
       
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
       
      Not applicable.
       
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      Not applicable.
       
    Item 8.
    Identification and Classification of Members of the Group.
       
      Not applicable.
       
    Item 9.
    Notice of Dissolution of Group.
       
      Not applicable.
       
    Item 10.
    Certifications.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:  February 15, 2021

     
    The Alaska Permanent Fund Corporation*
     
     
     
     
     
    By:
    /s/ Angela Rodell                    
     
    Name:
    Angela Rodell
     
    Title:
    Chief Executive Officer


    *The Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of the Reporting Persons’ pecuniary interest therein.

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).


    Get the next $CDAK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDAK

    DatePrice TargetRatingAnalyst
    2/22/2022$34.00 → $24.00Outperform
    Wedbush
    2/11/2022$19.00Buy
    Goldman Sachs
    More analyst ratings

    $CDAK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process

      CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the Company has voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and will seek to pursue a sale process for its assets which is intended to maximize the value of the Company. The Company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several parties. The Company expects

      3/27/23 7:00:00 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference

      CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be participating in the 5th Annual Evercore ISI HealthCONx Conference, a virtual conference. Codiak's Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat on Wednesday, November 30 at 8:00 am ET and the Company will also be hosting one-on-one meetings at the conference. A live webcast of the fireside chat will be available on the Investors & Media section of the Codiak website at www.codiakbio.com. A

      11/28/22 1:00:00 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

      – exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models; biomarkers with clinical translational potential identified, providing a rationale for selecting cancer subtypes for treatment with exoASO-STAT6 – – Systemically administered exoASO-C/EBPβ demonstrated extra-hepatic delivery and potent systemic anti-tumor activity across multiple myeloid-derived suppressor cell (MDSC) rich tumor models – – A Phase 1 clinical trial of exoASO-STAT6 in patients with advanced hepatocellular carcinoma (HCC), is ongoing; initial data expected in the first half of 2023 – CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a

      11/10/22 9:00:00 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush reiterated coverage on Codiak BioSciences with a new price target

      Wedbush reiterated coverage of Codiak BioSciences with a rating of Outperform and set a new price target of $24.00 from $34.00 previously

      2/22/22 8:48:06 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Goldman Sachs initiated coverage on Codiak BioSciences with a new price target

      Goldman Sachs initiated coverage of Codiak BioSciences with a rating of Buy and set a new price target of $19.00

      2/11/22 6:11:40 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDAK
    Financials

    Live finance-specific insights

    See more
    • Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™

      – Codiak's engineered exosome candidates demonstrate potential for best-in-class profile, with tumor retention and delivery to the cells of interest allowing for increased therapeutic window – – exoSTING and exoIL-12 demonstrated favorable safety and tolerability profile at repeat doses tested and antitumor activity was observed in both injected and uninjected/distal lesions – – Codiak has identified recommended Phase 2 dose for each program and plans to initiate Phase 2 studies for both candidates in the first quarter of 2023 – – Codiak to host conference call and webcast today at 8:00 am ET – CAMBRIDGE, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK),

      6/30/22 6:30:00 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Codiak BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress

      – Reported positive initial data from exoSTING™ clinical trial; on track to provide data from all dose escalation cohorts in late 1H 2022 – – Investigational New Drug (IND) application cleared for exoASO™-STAT6, with clinical trial initiation expected 1H 2022 –                   – Initial safety, PK/PD and efficacy data for exoIL-12™ in CTCL patients anticipated late 1H 2022 – – Progressed preclinical pan-beta coronavirus vaccine program – CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today reported fourth quarte

      3/10/22 4:01:00 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts

      – exoSTING resulted in localized STING pathway activation and dose-dependent immune activation – – Intratumoral administration of exoSTING was well tolerated and demonstrated tumor retention, no systemic exposure to STING agonist, and in a subset of patients, tumor shrinkage in injected and distal non-injected lesions – – Data on objective response rate and recommended Phase 2 dose selection for expansion anticipated 1H 2022 – – Codiak to host conference call and webcast today at 8:00 am ET – CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therap

      11/16/21 6:45:00 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDAK
    Leadership Updates

    Live Leadership Updates

    See more
    • Codiak Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer

      CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the appointment of David Mauro, M.D., Ph.D., a veteran oncology and immunotherapy drug developer, as Chief Medical Officer. Dr. Mauro will provide leadership and expertise for Codiak's pipeline of clinical development programs through early-stage trials to global regulatory submissions and joins the company's Executive Leadership Team reporting to Douglas E. Williams, Ph.D., President and CEO. "We have been fortunate to work with David since late last year

      5/2/22 9:00:00 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of Alltrna

      Werner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened its executive leadership team with the appointment of Michelle C. Werner to the dual role of CEO-Partner of Flagship Pioneering and Chief Executive Officer of Alltrna. Werner brings to Flagship significant experience as a global pharmaceutical leader spanning both Commercial and Research and Development (R&D) responsibilities.  Werner most recently served as Wo

      4/11/22 6:00:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations
    • Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

      CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for

      2/28/22 9:00:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations

    $CDAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Howze Yalonda

      4 - Codiak BioSciences, Inc. (0001659352) (Issuer)

      3/30/23 6:01:07 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Sathyanarayanan Sriram

      4 - Codiak BioSciences, Inc. (0001659352) (Issuer)

      3/30/23 5:19:21 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Konstantinov Konstantin

      4 - Codiak BioSciences, Inc. (0001659352) (Issuer)

      3/30/23 5:13:35 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Codiak BioSciences Inc. (Amendment)

      SC 13G/A - Codiak BioSciences, Inc. (0001659352) (Subject)

      2/14/24 2:23:36 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Codiak BioSciences Inc. (Amendment)

      SC 13G/A - Codiak BioSciences, Inc. (0001659352) (Subject)

      4/10/23 9:37:12 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Codiak BioSciences Inc. (Amendment)

      SC 13G/A - Codiak BioSciences, Inc. (0001659352) (Subject)

      2/14/23 1:02:51 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDAK
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Codiak BioSciences Inc.

      25-NSE - Codiak BioSciences, Inc. (0001659352) (Subject)

      5/2/23 1:35:25 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form NT 10-K filed by Codiak BioSciences Inc.

      NT 10-K - Codiak BioSciences, Inc. (0001659352) (Filer)

      3/28/23 7:34:56 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Codiak BioSciences Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Codiak BioSciences, Inc. (0001659352) (Filer)

      3/27/23 9:59:55 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care